loading...| Preferred Name |
aflibercept |
|
| Synonyms |
|
|
| ID |
http://purl.obolibrary.org/obo/dinto_DB08885 |
|
| AHFScode |
10:00 52:92 |
|
| ATCCode |
S01LA05 |
|
| binds |
http://purl.obolibrary.org/obo/dinto_0012 |
|
| CASRN |
862111-32-8 |
|
| DBBrand |
zaltrap eylea |
|
| DBSynonym |
vegf trap ave 0005 ziv-aflibercept ave-0005 vegf trap-eye ave 005 |
|
| Definition |
Aflibercept is a recombinant fusion protein that comprises of two main components: the vascular endothelial growth factor (VEGF) binding portions from the extracellular domains of human VEGF receptors 1 and 2 which is then fused to the Fc portion of human IgG1. Aflibercept, as an ophthalmic agent, is used in the treatment of macular edema following Central Retinal Vein Occlusion (CRVO) and neovascular Age-Related Macular Degeneration (AMD). Ziv-aflibercept, under the brand name Zaltrap, was developed as an injection for treatment of metastatic colorectal cancer. FDA approved in November 18, 2011 and EMA approved in November 2012. |
|
| has pharmacological target |
http://purl.obolibrary.org/obo/dinto_0012 |
|
| label |
aflibercept |
|
| prefixIRI |
obo2:dinto_DB08885 |
|
| prefLabel |
aflibercept |
|
| xref |
Wikipedia:http://en.wikipedia.org/wiki/Aflibercept RxList:http://www.rxlist.com/eylea-drug.htm National Drug Code Directory:61755-005-02 Drugs.com:http://www.drugs.com/mtm/aflibercept-ophthalmic.html |
|
| subClassOf |